Operational KPIs
No quarterly operational KPIs found in SEC filings for this company.
Citable operating metrics
GILD's latest SEC-sourced operating KPI table includes Acquired Ipr And D Expenses at 4990.00 for 2019-12-31.
| Metric | Period | Value | Basis |
|---|---|---|---|
| Acquired Ipr And D Expenses | Dec 31, 2019 | 4990.00 | quarterly |
| Cell Therapy Product Sales | Dec 31, 2020 | 5067.00 | quarterly |
| Descovy Sales Full Year | Dec 31, 2018 | 2018.00 | quarterly |
| Effective Tax Rate | Dec 31, 2016 | 18.00 | quarterly |
| Europe Product Sales | Sep 30, 2014 | 1.44 | quarterly |
| Hbv Hdv Product Sales | Dec 31, 2023 | 7070.00 | quarterly |
| Hcv Product Sales | Dec 31, 2023 | 7070.00 | quarterly |
| Hiv Product Sales | Dec 31, 2017 | 5837.00 | quarterly |
Source: SEC EDGAR operating KPI disclosure; period Dec 31, 2019; filed Oct 24, 2019; accession 0000882095-19-000024.
Continue research
Follow same-sector companies and source explainers connected to the kpis view.
A factual guide to operating KPIs — the company-specific metrics in filings, why they are not standardized, and how Aerarium Research surfaces them.
A factual guide to deferred revenue, cash collected before revenue is earned, and why the liability can matter for recurring businesses.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to seasonal revenue patterns and comparable (same-store) sales — why year-over-year comparisons matter and what comp sales strip out.